New PET scan agent could spot bladder cancer earlier
NCT ID NCT04897763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new imaging agent called 89Zr-girentuximab in 6 people with non-muscle-invasive bladder cancer. The goal was to see if it could safely and clearly show tumors on PET/CT scans. Researchers looked for uptake spots in the bladder and checked for side effects up to 30 days after injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut de cancerologie de l'Ouest
Saint-Herblain, 44805, France